How do you differentiate between Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML) in a patient based on their Complete Blood Count (CBC) results and clinical presentation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Differentiating AML from CML on CBC

CML presents with marked leukocytosis (often >100 × 10⁹/L) with a full spectrum of myeloid maturation including metamyelocytes, myelocytes, and promyelocytes, basophilia, and typically preserved or elevated platelets, while AML shows variable white counts with circulating blasts, cytopenias (anemia and thrombocytopenia), and lacks the orderly maturation seen in CML. 1, 2

CML CBC Picture

White Blood Cell Characteristics

  • Extreme leukocytosis is the hallmark, frequently exceeding 100 × 10⁹/L 3
  • Complete myeloid maturation spectrum present: predominantly metamyelocytes, myelocytes, and segmented forms, with few or occasional myeloblasts (<5%) 1
  • Basophilia is characteristic and diagnostically important 1
  • Eosinophils may be prominent 1

Other CBC Features

  • Thrombocytosis is frequent - platelets often elevated or preserved 1, 3
  • Severe anemia is rare at presentation 1
  • Leukostatic symptoms (priapism, dyspnea, confusion) are uncommon despite extreme WBC counts 1

AML CBC Picture

White Blood Cell Characteristics

  • Variable WBC count - can be low, normal, or elevated (not typically as extreme as CML) 2
  • Circulating blasts are common, though blast percentage varies 1
  • Lack of orderly myeloid maturation - no full spectrum of maturing granulocytes 1
  • Blasts must comprise ≥20% of bone marrow cells for diagnosis (with exceptions for specific cytogenetic abnormalities) 1

Other CBC Features

  • Cytopenias are typical: anemia and thrombocytopenia from bone marrow failure 2
  • Neutropenia with leukocyte dysfunction leads to infections 2
  • Easy bleeding/bruising from thrombocytopenia and platelet dysfunction 2

Clinical Presentation Differences

CML Presentation

  • Often asymptomatic - approximately 40% diagnosed incidentally on routine blood work 1
  • Massive splenomegaly with hepatomegaly when symptomatic 3
  • Constitutional symptoms (weight loss, fatigue, sweats) are non-specific and less prominent 1
  • Symptoms from splenomegaly (left upper quadrant fullness/pain) 1

AML Presentation

  • Symptomatic at presentation - fatigue, bleeding, and fever are most common 2
  • Splenomegaly and hepatomegaly are less common (unlike CML) 2
  • Lymphadenopathy in approximately 20% 2
  • Severe constitutional symptoms including fever, night sweats, weight loss 2

Confirmatory Testing Required

For CML

  • BCR-ABL1 testing is mandatory - either by FISH or RT-PCR to confirm diagnosis before initiating therapy 1, 3
  • Cytogenetics showing t(9;22)(q34;q11) Philadelphia chromosome 1
  • Bone marrow shows hypercellularity with granulocytic proliferation, blasts <5%, and characteristic "dwarf megakaryocytes" 1

For AML

  • Bone marrow aspirate showing ≥20% myeloblasts (or specific cytogenetic abnormalities regardless of blast count) 1
  • Cytogenetics and molecular testing for risk stratification 1
  • BCR-ABL1 must be negative to exclude CML 1
  • Immunophenotyping by flow cytometry for lineage determination 1

Critical Pitfall to Avoid

Never rely solely on CBC to differentiate these entities - while the CBC patterns are highly suggestive, molecular confirmation with BCR-ABL1 testing is essential because CML in blast crisis can mimic AML, and both require fundamentally different treatment approaches (tyrosine kinase inhibitors for CML vs. intensive chemotherapy for AML) 1, 3. The presence of BCR-ABL1 fusion definitively establishes CML diagnosis and directs therapy toward TKI treatment rather than standard AML chemotherapy 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Clinical Presentation of Acute Myeloid Leukemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnosis and Management of Chronic Myeloid Leukemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the most appropriate next step in management for a patient with acute myeloid leukemia (AML) on chemotherapy, presenting with fever and pancytopenia, with normal chest radiograph and urinalysis?
What is the best treatment approach for a patient diagnosed with Acute Myeloid Leukemia (AML), considering their overall health status, age, and potential comorbidities such as heart disease?
What are the diagnostic criteria and treatment options for a 60-year-old adult with suspected acute myeloid leukemia (AML)?
What are the differences in treatment approaches for Acute Myeloid Leukemia (AML) versus Acute Lymphoblastic Leukemia (ALL)?
What is the 5-year survival rate for a patient with Acute Myeloid Leukemia (AML) who underwent chemotherapy initially and then required a bone marrow transplant due to recurrence?
How would you control patient synchrony in mechanical ventilation?
Can asymptomatic bacteriuria show hypermetabolic retrocaval lomboaortic lymph nodes on a Positron Emission Tomography (PET) scan in a patient with a history of diabetes or immunocompromised state?
What is the approach to managing fever in a critically ill ICU patient with a severe fungal infection and impaired renal function?
What is the treatment for an adult patient with no significant medical history presenting with bleeding gums and sensitive teeth?
What are the typical laboratory and physical findings in a patient with Chronic Myeloid Leukemia (CML)?
Can a patient with a colonized JJ (double J) stent, presenting with flank pain and no fever, and infected with Morganella morganii and Enterococcus faecalis, show ambiguous results on a PET (positron emission tomography) scan with hypermetabolic retrocaval lomboaortic lymph nodes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.